Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Deffered Revenue (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 14 years of Non-Current Deffered Revenue data on record, last reported at $12.4 million in Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 14.25% year-over-year to $12.4 million; the TTM value through Dec 2025 reached $12.4 million, down 14.25%, while the annual FY2025 figure was $12.4 million, 14.25% down from the prior year.
  • Non-Current Deffered Revenue reached $12.4 million in Q4 2025 per LCTX's latest filing, down from $12.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $30.8 million in Q1 2022 and bottomed at $12.4 million in Q4 2025.
  • Average Non-Current Deffered Revenue over 4 years is $19.7 million, with a median of $18.6 million recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: tumbled 32.58% in 2023, then decreased 14.25% in 2025.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $27.7 million in 2022, then crashed by 32.58% to $18.7 million in 2023, then fell by 22.79% to $14.4 million in 2024, then dropped by 14.25% to $12.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $12.4 million in Q4 2025, $12.5 million in Q3 2025, and $12.8 million in Q2 2025.